10-K Filing: Key information for Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. has filed its Form 10-K Annual Report for the period ending on September 30, 2024. This filing provides valuable insights into the company’s financial performance, operations, and risk factors as required by the Securities and Exchange Commission. Investors and stakeholders can access the full document, along with additional exhibits, on the SEC website.
Attachments:
1. Document: 10-K Filing
2. Document: EX-4.1
3. Document: EX-10.11
For further information, interested parties can also review the complete submission text file on the SEC website. The filing includes essential data files such as EX-101.SCH, EX-101.CAL, EX-101.DEF, EX-101.LAB, and EX-101.PRE. These files provide detailed information about the company’s financial statements and disclosures.
Moreover, Outlook Therapeutics, Inc. is a Delaware-based company specializing in biological products without diagnostic substances. With a fiscal year ending on September 30, the company’s business address is located at 111 S. Wood Avenue, Unit #100, Iselin, NJ 08830. For inquiries, they can be reached at 609-619-3990. Investors keen on understanding the company’s financial health and strategic direction can delve into the Form 10-K filing for comprehensive insights.
[Company Website](#)
Original Filing
